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OBJECTIVES The Air Primary Angioplasty in Myocardial Infarction (PAMI) study was designed to
determine the best reperfusion strategy for patients with high-risk acute myocardial infarction
(AMI) at hospitals without percutaneous transluminal coronary angioplasty (PTCA) capa-
bility.
BACKGROUND Previous studies have suggested that high-risk patients have better outcomes with primary
PTCA than with thrombolytic therapy. It is unknown whether this advantage would be lost
if the patient had to be transferred for PTCA, and reperfusion was delayed.
METHODS Patients with high-risk AMI (age 70 years, anterior MI, Killip class II/III, heart rate 100
beats/min or systolic BP 100 mm Hg) who were eligible for thrombolytic therapy were
randomized to either transfer for primary PTCA or on-site thrombolysis.
RESULTS One hundred thirty-eight patients were randomized before the study ended (71 to transfer for
PTCA and 67 to thrombolysis). The time from arrival to treatment was delayed in the
transfer group (155 vs. 51 min, p  0.0001), largely due to the initiation of transfer (43 min)
and transport time (26 min). Patients randomized to transfer had a reduced hospital stay
(6.1  4.3 vs. 7.5  4.3 days, p  0.015) and less ischemia (12.7% vs. 31.8%, p  0.007).
At 30 days, a 38% reduction in major adverse cardiac events was observed for the transfer
group; however, because of the inability to recruit the necessary sample size, this did not
achieve statistical significance (8.4% vs. 13.6%, p  0.331).
CONCLUSIONS Patients with high-risk AMI at hospitals without a catheterization laboratory may have an
improved outcome when transferred for primary PTCA versus on-site thrombolysis; however,
this will require further study. The marked delay in the transfer process suggests a role for
triaging patients directly to specialized heart-attack centers. (J Am Coll Cardiol 2002;39:
1713–9) © 2002 by the American College of Cardiology Foundation
Angioplasty as the primary reperfusion strategy for acute
myocardial infarction (AMI) reduces recurrent ischemia,
reinfarction, stroke and death, compared with thrombolytic
See page 1720
therapy (1–4). Despite these findings, thrombolytic therapy
remains the mainstay of therapy for AMI, partly due to the
fact that the majority of hospitals lack percutaneous trans-
luminal coronary angioplasty (PTCA) capabilities.
Although thrombolytic therapy remains an acceptable
alternative for most patients, it may not be ideal for
higher-risk patients. Advanced age, anterior infarction,
tachycardia, hypotension and congestive heart failure are
associated with early mortality rates ranging from 10% to
58% in patients treated with thrombolytic agents (5). Some
trials suggested that high-risk patients have the greatest
benefit from primary PTCA, when compared with throm-
bolysis (1,6). However, none of these earlier trials involved
the transfer of patients from a primary-care hospital, a
strategy that would substantially delay the time to reperfu-
sion.
Observational studies reported few complications during
transfer for primary PTCA and no correlation between
transfer distance and adverse outcome (7,8). Moreover,
although the efficacy of thrombolysis decreases with the
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increasing age of the clot (9–11), coronary patency and
clinical outcomes after primary PTCA appear to be inde-
pendent of the time to treatment (12–14). Therefore, the
benefits of primary PTCA may overcome the deleterious
effects of the delay in reperfusion during the time required
to transfer. We hypothesized that in hospitals without an
interventional laboratory, patients with high-risk AMI
would have improved clinical outcomes if transferred for
primary PTCA, rather than being treated with conven-
tional, on-site thrombolytic therapy.
METHODS
Patient selection. Patients were considered if they had
either ST-segment elevation or presumed new left bundle
branch block and the onset of AMI was12 h. In addition,
one or more of the following criteria for high risk had to be
met: age 70 years, heart rate 100 beats/min, systolic
blood pressure (BP)100 mm Hg in the absence of volume
depletion, Killip class II/III or an electrocardiogram (ECG)
demonstrating left bundle branch block or anterior MI.
Patients were excluded from study participation if they
were ineligible for thrombolytic therapy (history of stroke or
transient cerebral event in the last six months, major surgery
or active gastrointestinal bleeding within the previous two
months, organ biopsy within two weeks, cardiopulmonary
resuscitation lasting 10 min or resulting in rib fracture,
systolic BP 200 mm Hg or diastolic BP 110 mm Hg),
had cardiogenic shock (defined as systolic BP 80 mm Hg
in the absence of bradycardia or requiring vasopressors) or
had a life-expectancy of less than one year. The study was
conducted according to the principles of the Declaration of
Helsinki, and all patients gave written, informed consent.
Eligible high-risk patients were randomized to receive
either emergent transfer for primary PTCA or on-site throm-
bolytic therapy. Randomization was stratified by site and
accomplished by either telephone randomization from the
study coordinating center (U.S. sites) or sealed envelope
(non-U.S. sites). The protocol recommended low-flow nasal
oxygen, nitroglycerin, oral aspirin (325 mg) and intravenous
beta-blockers. Anti-arrhythmic agents and calcium blockers
were not routinely administered. Heparin was given according
to the treatment arm to which the patient was assigned.
Transfer for primary PTCA arm. For patients random-
ized to primary angioplasty, emergency transfer was ar-
ranged by the most expedient means (either air or ground
transport) to the assigned interventional facility. As soon as
possible after randomization, a bolus of intravenous heparin
was administered, but a continuous infusion was not rec-
ommended.
Patients were taken to the cardiac catheterization labo-
ratory immediately upon arrival. Coronary angiography and
left ventriculography were performed using low-osmolar
ionic contrast medium (ioxaglate, Mallinckrodt, Inc., St.
Louis, Missouri). A coronary intervention was performed
unless the following exclusions precluded PTCA: infarct
vessel stenosis 70%, an infarct vessel supplying so little to
the myocardium that the PTCA risk outweighed the
benefit, unprotected left main stenosis 60% or disease
requiring coronary artery bypass graft surgery (CABG). The
goal of angioplasty was restoration of normal coronary flow
with minimal residual stenosis. Stenting was encouraged for
residual lesions 30% or the presence of a coronary dissec-
tion. The activated clotting time was maintained at 350 s,
and administration of thrombolytic agents was discouraged.
Thrombolytic treatment arm. Patients randomized to
thrombolytic therapy received the drug that was considered
the standard of care for the participating hospital. If tissue
plasminogen activator was administered, heparin was given
as an intravenous bolus, followed by an infusion for 72 h,
with the dose adjusted to raise the activated partial throm-
boplastin time between 60 and 80 s. If streptokinase was
given, heparin was administered according to the usual
practice of the patient’s physician. Patients randomized to
thrombolysis remained at the enrolling hospital unless it was
the usual practice to transfer patients with AMI. For
patients with persistent chest pain, recurrent chest pain or
hemodynamic instability, it was recommended that emer-
gency catheterization be considered.
Clinical end points. The primary end point (i.e., major
adverse cardiac events [MACE]) was the combined occur-
rence of death, non-fatal reinfarction or disabling stroke at
30 days. It was estimated that enrollment of 430 patients
was required, assuming an event rate of 25% in the throm-
bolytic arm and a 40% reduction in events, with a power
80%. Reinfarction was defined as recurrent ischemic symp-
toms in association with re-elevation of creatine kinase to
three times the upper limit of normal. Disabling stroke was
defined as neurologic deficits significantly affecting activities
of daily life. Ischemia was defined as persistent ischemic
chest pain after reperfusion therapy or recurrent symptoms
with ST-segment changes, new heart failure, murmur or
creatine kinase re-elevation.
Detailed case-report forms were completed by the clinical
coordinators at each site. Monitoring of the case-report
form and hospital records was performed by the Primary
Angioplasty in Myocardial Infarction (PAMI) coordinating
center. All primary end points, as well as a random sampling
of 20% of patients, were reviewed by the clinical events
Abbreviations and Acronyms
AMI  acute myocardial infarction
BP  blood pressure
CABG  coronary artery bypass graft surgery
CI  confidence interval
ECG  electrocardiogram
MACE  major adverse cardiac events
OR  odds ratio
PAMI  Primary Angioplasty in Myocardial Infarction
study
PTCA  percutaneous transluminal coronary angioplasty
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committee, which was blinded to the treatment received.
The case-report form was never completed for one patient
randomized to on-site lytic therapy. The clinical site with-
drew from the trial after randomizing one patient and
declined to provide any further information.
Statistical analyses. Categorical variables, including the
end points of death, reinfarction, disabling stroke and the
combined primary end point of MACE, were examined
using the chi-square or Fisher two-sided exact test, as
appropriate. Continuous variables were examined using the
Wilcoxon rank-sum test because some of the variables
were not normally distributed. A step-down logistic
regression analysis was completed for 30-day MACE,
including independent variables with a p value 0.15.
History of previous MI, diabetes, type of lytic therapy,
U.S. versus non-U.S. site, and time to treatment were
included regardless of the p value. All analyses were
completed using SAS, version 8.0.
RESULTS
Demographic data and high-risk characteristics. The
study was terminated after 39 months, and 138 patients
(32% of the anticipated sample size) were randomized. The
Steering Committee decided to terminate the trial before
knowledge of any of the event rates, because of poor
recruitment. At that time, 71 patients had been randomized
to transfer and 67 patients to on-site thrombolysis. The
demographic data and high-risk enrollment criteria of the
transfer and thrombolysis groups are outlined in Table 1.
Treatments and time delays. All of the 71 patients ran-
domized to transfer were transferred (79% by ambulance
and 21% by helicopter). Overall, the mean distance was
32  36 miles (25th, 50th and 75th percentiles were 10, 16
and 43 miles, respectively). In general, air transfer was used
for greater distances (57 50 miles), compared with ground
transfer (26  28 miles). No patient died or required
cardiopulmonary resuscitation during transfer, and minor
events during transfer were observed in only three patients
(2 with hypotension and 1 with confusion).
Patients transferred for PTCA had the longest time to
treatment (155 vs. 51 min, p  0.0001), due to the time
involved in the transfer and starting the invasive procedure
(Table 2). Among the transfer group, 100% underwent
catheterization, 89% had primary PTCA, and 87% had
normal flow (TIMI grade 3) established (Table 3). Eight
patients randomized to transfer did not receive primary
PTCA; two patients were treated medically; and six patients
Table 1. Air Primary Angioplasty in Myocardial Infarction
Study: Baseline Characteristics
Variable
Transfer for
Primary PTCA
(n  71)
On-Site
Lytic Therapy
(n  66)
p
Value
Age (yrs) 62  12 64  12 0.59
Gender (%male) 76 65 0.16
Hypertension (%) 51 34 0.04
History of peripheral
vascular disease (%)
10 5 0.32
Previous MI (%) 13 14 0.89
Previous CABG (%) 3 3 1.00
Diabetes (%) 23 20 0.68
High-risk qualifiers (%)
Age 70 years 27 39 0.12
Heart rate 100 beats/min 37 27 0.24
SBP 100 mm Hg 38 27 0.18
Killip class I 35 23 0.20
Anterior MI 77 80 0.68
ECG with LBBB 4 2 0.62
Two or more qualifiers 63 58 0.49
Three or more qualifiers 34 27 0.41
Data are presented as the mean value  SD or percentage of patients.
CABG  coronary artery bypass graft surgery; ECG  electrocardiogram;
LBBB  left bundle branch block; MI  myocardial infarction; PTCA 
percutaneous transluminal coronary angioplasty; SBP  systolic blood pressure.
Table 2. Air Primary Angioplasty in Myocardial Infarction Trial: Time to Treatment
Transfer for PTCA Lytic Therapy
p ValueIntervals
Median
(25th, 75th) Mean  SD
Median
(25th, 75th) Mean  SD
Emergency center arrival to randomization 35 (20,53) 52  57 32 (15,65) 44  37 0.67
Randomization to call for transfer 6 (5,15) 15  30
Transfer call to transfer, arrives at hospital no. 1 20 (10,26) 23  18
Transfer arrives to transfer leaves hospital no. 1 12 (9,17) 14  9
Transfer time 26 (15,40) 33  29
Arrival at hospital no. 2 to catheterization laboratory 11 (5,20) 20  49
Catheterization laboratory arrival to treatment 14 (8,23) 18  14
ER to treatment 155 (118,194) 174  80 51 (35,89) 63  39  0.0001
ER  emergency room; PTCA  percutaneous transluminal coronary angioplasty.
Table 3. Air Primary Angioplasty in Myocardial Infarction
Study: Treatments Received
Transfer for
PTCA
On-Site Lytic
Therapy
Intravenous lytic therapy 1 (1.4%) 66 (100%)
Catheterization 71 (100%) 36 (55%)
Revascularization 68 (96%) 34 (52%)
PTCA 62 (87%) 27 (41%)
CABG 10 (14%) 7 (11%)
Aspirin 68 (96%) 63 (95%)
ACE inhibitors 48 (68%) 43 (65%)
Beta-blockers 36 (51%) 45 (68%)
Digoxin 9 (12.7%) 6 (9.1%)
ACE  angiotensin-converting enzyme; other abbreviations as in Table 1.
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were referred for CABG. The mean ejection fraction was
47  12%; 62% of patients were noted to have multivessel
disease, and 34% received one or more stents.
Among patients randomized to on-site thrombolysis,
68% received a fibrin-specific agent (alteplace or reteplase)
and 32% received streptokinase. Within the first 30 days,
catheterization was performed in 55%, and revascularization
with PTCA or CABG in 52%, of patients randomized to
on-site thrombolysis.
Clinical outcomes. Patients randomized to transfer for
primary PTCA had a shorter length of hospital stay (6.1 
4.3 vs. 7.5  4.3 days, p  0.015) and less ischemia (12.7%
vs. 31.8%, p  0.007) (Fig. 1). At 30 days, 8.4% of patients
randomized to transfer reached the primary end point of
death, non-fatal reinfarction or disabling stroke, compared
with 13.6% of patients in the on-site thrombolysis group
(odds ratio [OR] 0.571, 95% confidence interval [CI]
0.191 to 1.709, p  0.331). In a secondary, pre-specified
analysis using step-down, multivariate, logistic regres-
sion, randomization to transfer for primary PTCA was
independently associated with a reduction in the primary
end point (OR 0.159, 95% CI 0.031 to 0.820, p  0.028)
(Table 4).
DISCUSSION
This trial demonstrated that patients with high-risk AMI at
hospitals without PTCA capabilities might have an im-
proved outcome if transferred for emergency PTCA rather
than being treated with thrombolytic therapy. Although our
study was too small to achieve statistical significance, a 38%
reduction in MACE was observed. Our findings are con-
sistent with those in other recently reported randomized
Figure 1. Thirty-day clinical events were non-significantly improved in the group transferred for primary percutaneous transluminal coronary angioplasty
(PTCA). CVA  cerebrovascular accident; MACE  major adverse cardiac events (i.e., combined end point of death, repeat MI and disabling stroke);
reMI  non-fatal reinfarction.
Table 4. Air Primary Angioplasty in Myocardial Infarction
Study: Multivariate Predictors of Major Adverse Cardiac Events
at 30 Days
Variable
Odds
Ratio
95%
Confidence
Interval p Value
SBP 100 mm Hg 19.00 3.20–113 0.0012
Heart rate 100 beats/min 10.23 2.23–46.9 0.0028
Age 70 years 7.18 1.60–32.2 0.0100
Randomization to
thrombolytic therapy
6.29 1.22–32.3 0.0278
History of hypertension 5.10 0.969–26.9 0.0545
SBP  systolic blood pressure.
Major adverse cardiac events  combined end point of death, repeat myocardial
infarction or disabling stroke.
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trials demonstrating improved outcomes with transfer for
primary PTCA (15,16).
Transfer of patients with AMI. Despite enrollment of
only high-risk patients, transfer in the early hours of AMI
was found to be safe. However, the time delay in initiating
the transfer (mean 52 min, median 38 min) was much
longer than expected, and it added significantly to the delay
in establishing reperfusion. As shown in Table 2, the delay
in starting the transfer was multifactorial, but the greatest
component was the wait for the ambulance or helicopter to
arrive. The policy of some emergency medical systems is to
assign a low priority to a patient who is already at a medical
facility. Although there is some rationale for this policy, an
exception should be made for patients with AMI requiring
mechanical reperfusion. Moreover, the transferring and
receiving institutions should work out the transfer logistics
in advance to improve their response time.
Mechanism of benefit of primary PTCA. Transfer to a
hospital where the patient will be managed by a cardiologist
may result in greater utilization of proven medical therapies
(17). We did not find this, but participating centers may not
be representative of a non-study situation. Paradoxically, we
found greater utilization of beta-blockers in the thrombo-
lytic group, possibly due to treatment of recurrent angina,
which occurred more frequently after thrombolytic therapy.
Avoiding the use of thrombolytic agents clearly reduces the
risk of intracranial bleeding (4), and previous randomized
trials have shown reduced rates of reinfarction with PTCA
(1–4). Primary angioplasty reduces the coronary stenosis
that may predispose the vessel to reocclusion (18–20), and
it avoids the platelet-aggregating effects of thrombolytic
agents (21,22). Trials with angiographic follow-up suggest
that patients treated with primary PTCA (2,23,24) have
substantially lower rates of reocclusion, compared with
those treated by thrombolytic therapy (18,19,25,26), and
reocclusion may be further reduced by stent placement (27).
The greatest benefit of primary PTCA may be its ability to
achieve90% rates of normal coronary flow (28) even when
the patient is treated in the late stages of infarction (13,14).
By contrast, thrombolytic therapy has a marked decrease in
thrombolytic efficacy in patients treated more than a few
hours after symptom onset (9,10).
Should thrombolytic agents be given before transfer?
We have shown that the presence of spontaneous reperfu-
sion before primary PTCA was an independent predictor of
survival (29). Accordingly, there has been great interest in
the concept of “facilitated” PTCA, whereby the patient is
given a reduced dose of a thrombolytic agent, with an
adjunctive glycoprotein IIb/IIIa or thrombin inhibitor.
Theoretically, these combinations are attractive; however,
two large randomized trials found no reduction in the
primary end point of mortality, and there was a suggestion
of a slight increase in intracranial bleeding (30,31). Al-
though combination therapies were associated with less
reinfarction in these trials, this was considered a soft end
point because this strategy was not adjudicated by an
independent events committee or because the study was not
blinded, or both. Moreover, these trials did not incorporate
a primary or facilitated angioplasty arm. The only random-
ized trial of facilitated percutaneous coronary intervention
found that pre-treatment with tissue plasminogen activator
improved the pre-procedural coronary patency but had no
influence on the post-PTCA flow, ejection fraction or
clinical outcome (32). More pertinent to this question are
the PRAGUE and LIMI trials, both of which randomized
patients with AMI at small community hospitals to transfer
for primary PTCA, on-site lytic therapy, or a third arm of
lytic administration before transfer (15,16). Both trials
reported higher rates of bleeding in patients given lytic
agents before transfer and worse clinical outcome compared
with primary PTCA alone. Therefore, the available data
suggest no benefit (32) or potential harm (15,16,23,30–35)
by pre-treatment with thrombolytic agents before PTCA.
Primary angioplasty in hospitals without on-site surgical
support. An emerging practice in some hospitals that have
diagnostic catheterization laboratories is to perform on-site
primary PTCA without surgical backup. A large, single-
center experience (36), a retrospective review of a multi-
center AMI registry (37) and a 500-patient, prospective,
multicenter registry (38,39) suggest excellent clinical and an-
giographic outcomes if PTCA is performed by an experienced
operator. The Cardiovascular Patient Outcomes Research
Team (C-PORT) multicenter study randomized 451 patients
with AMI at hospitals without surgical backup to receive
on-site PTCA or thrombolytic therapy (40). They reported a
38% reduction in the primary end point of death, reinfarction
or stroke at six months (12.4% vs. 19.9%, p 0.03). Based on
these reports, the American College of Cardiology/American
Heart Association’s guidelines for PTCA have been modified
to consider primary PTCA as a class II indication at centers
without on-site surgical capability (41).
Clinical implications. Given the small sample size of this
trial, one must use caution when interpreting the results.
Our study suggests that when a patient presents to a hospital
that cannot perform primary PTCA, transfer for PTCA
may be superior to on-site lytic therapy. Our results are
corroborated by two other trials, but the number of patients
enrolled in all three trials is low. Although these findings are
provocative, they need to be confirmed in a large trial before
any general recommendations can be made. On the other
hand, we found that even in this study situation, the transfer
process is slow, with long delays at each component. This
suggests that there may be a role for obtaining ECGs in the
field, transferring the patient directly from the home to a
“heart-attack center” or even providing primary PTCA in
smaller hospitals without on-site surgical capability.
Reprint requests and correspondence: Dr. Cindy L. Grines,
William Beaumont Hospital, Cardiology Administration, 3rd
Floor, Heart Center, 3601 West Thirteen Mile Road, Royal Oak,
Michigan 48073-6769.E-mail: cgrines@beaumont.edu.
1717JACC Vol. 39, No. 11, 2002 Grines et al.
June 5, 2002:1713–9 Transfer for Primary PTCA vs. On-Site Thrombolysis
REFERENCES
1. Grines CL, Browne KF, Marco J, et al the Primary Angioplasty in
Myocardial Infarction Study Group. N Engl J Med 1993;328:
673–9.
2. Zijlstra F, de Boer MJ, Beukema WP, et al. Mortality, reinfarction,
left ventricular ejection fraction and costs following reperfusion ther-
apies for acute myocardial infarction. Eur Heart J 1996;17:382–7.
3. The GUSTO-IIb Angioplasty Substudy Investigators. A clinical
trial comparing primary coronary angioplasty with tissue plasmin-
ogen activator for acute myocardial infarction: the Global Use of
Strategies To Open occluded coronary arteries in acute coronary
syndromes (GUSTO-IIb) Angioplasty substudy (published erratum
appears in N Engl J Med 1997;337:287). N Engl J Med 1997;336:
1621–8.
4. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary
coronary angioplasty and intravenous thrombolytic therapy for acute
myocardial infarction: a quantitative review (published erratum appears
in. JAMA 1998;927:1876) JAMA 1997;278:2093–8.
5. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality
in the era of reperfusion for acute myocardial infarction: results from an
international trial of 41,021 patients. Circulation 1995;91:1659–68.
6. Grines CL, Ellis S, Jones M, et al. Primary coronary angioplasty vs.
thrombolytic therapy for acute myocardial infarction (MI): long-
term follow-up of 10 randomized trials. Circulation 1999;100 Suppl
I:I499.
7. Gore JM, Corrao JM, Goldberg RJ, et al. Feasibility and safety of
emergency inter-hospital transport of patients during early hours of
acute myocardial infarction. Arch Intern Med 1989;149:353–5.
8. Straumann E, Yoon S, Naegeli B, et al. Hospital transfer for primary
coronary angioplasty in high risk patients with acute myocardial
infarction. Heart 1999;82:415–9.
9. Cheseboro JH, Knatterud G, Roberts R, et al. Thrombolysis in
Myocardial Infarction trial, phase 1: a comparison between intravenous
tissue plasminogen activator and intravenous streptokinase. Circula-
tion 1987;76:142–54.
10. Bode C, Smalling RW, Berg G, et al. Randomized comparison of
coronary thrombolysis achieved with double-bolus reteplase (recom-
binant plasminogen activator) and front-loaded, accelerated alteplase
(recombinant tissue plasminogen activator) in patients with acute
myocardial infarction. The RAPID II Investigators. Circulation 1996;
94:891–8.
11. Newby LK, Rutsch WR, Califf RM, et al. Time from symptom onset
to treatment and outcomes after thrombolytic therapy. GUSTO-1
Investigators. J Am Coll Cardiol 1996;27:1646–55.
12. Stone GW, O’Keefe J, Brodie BR, O’Neill WW, Grines CL. Lack of
relationship between the time to reperfusion and short term mortality
after primary infarct angioplasty (abstr). J Am Coll Cardiol 1998;31
Suppl:271A.
13. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to
reperfusion for 30-day and late survival and recovery of left ventricular
function after primary angioplasty for acute myocardial infarction.
J Am Coll Cardiol 1998;32:1312–9.
14. Brodie BB, Stone GW, Morice MC, et al. The importance of time to
reperfusion on outcomes after primary angioplasty for acute myocardial
infarction: results from the Stent Primary Angioplasty in Myocardial
Infarction (PAMI) trial. Am J Cardiol 2001;88:1085–90.
15. Vermeer F, Oude Ophuis AJM, Vd Berg EJ, et al. Prospective
randomized comparison between thrombolysis, rescue PTCA, and
primary PTCA in patients with extensive myocardial infarction ad-
mitted to a hospital without PTCA facilities: a safety and feasibility
study. Heart 1999;82:426–31.
16. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F,
Suryapranata H. Multicentre randomized trial comparing transport to
primary angioplasty vs immediate thrombolysis vs combined strategy
for patients with acute myocardial infarction presenting to a commu-
nity hospital without a catheterization laboratory. The PRAGUE
study. Eur Heart J 2000;21:823–31.
17. Jollis JG, DeLong ER, Peterson ED, et al. Outcome of acute
myocardial infarction according to the specialty of the admitting
physician. N Engl J Med 1996;335:1880–7.
18. Meijer A, Verheugt FWA, Werter CJPJ, Lie KI, van der Pol JMJ, van
Eenige JM. Aspirin versus Coumadin in the prevention of reocclusion
and recurrent ischemia after successful thrombolysis: a prospective
placebo-controlled angiographic study—results of the APRICOT
study. Circulation 1993;87:1524–30.
19. White HD, French JK, Hamer AW, et al. Frequent reocclusion of
patent infarct-related arteries between 4 weeks and 1 year: effects of
antiplatelet therapy. J Am Coll Cardiol 1995;25:218–23.
20. Gibson CM, Cannon CP, Piana RN, et al. Angiographic predictors
of reocclusion after thrombolysis: results from the Thrombolysis in
Myocardial Infarction-4 trial. J Am Coll Cardiol 1995;25:582–9.
21. Kerins DM, Roy L, FitzGerald GA, Fitzgerald DJ. Platelet and
vascular function during coronary thrombolysis with tissue-type plas-
minogen activator. Circulation 1989;80:1718–25.
22. Bennett WR, Yawn DH, Migliore PJ, et al. Activation of the
complement system by recombinant tissue plasminogen activator.
J Am Coll Cardiol 1987;10:627–32.
23. O’Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-
controlled, randomized trial of intravenous streptokinase and angio-
plasty versus lone angioplasty therapy of acute myocardial infarction.
Circulation 1992;86:1710–7.
24. Brodie BR, Grines CL, Ivanhoe R, Knopf W, Taylor G, O’Keefe J, et
al. Six-month clinical and angiographic follow-up after direct angio-
plasty for acute myocardial infarction: final results from the Primary
Angioplasty Registry. Circulation 1994;90:156–62.
25. Topol EJ, Califf RM, George BS, et al. A randomized trial of
immediate versus delayed elective angioplasty after intravenous tissue
plasminogen activator in acute myocardial infarction. N Engl J Med
1987;317:581–8.
26. Brouwer MA, Van den Bergh PJPC, Vromans RPJW, et al. Aspirin
plus medium intensity Coumadin versus aspirin alone in the
prevention of reocclusion after successful thrombolysis for sus-
pected acute myocardial infarction (abstr). J Am Coll Cardiol
2001;37 Suppl:368A.
27. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or
without stent implantation for acute myocardial infarction. N Engl
J Med 1999;341:1949–56.
28. Grines CL. Should thrombolysis or primary angioplasty be the
treatment of choice for acute myocardial infarction? Primary angio-
plasty—the strategy of choice. N Engl J Med 1996;335:1313–6.
29. Stone GW, Cox D, Garcia E, et al. Normal flow (Thrombolysis in
Myocardial Infarction-3 study) before mechanical reperfusion ther-
apy is an independent determinant of survival in acute myocardial
infarction: analysis from the PAMI trials. Circulation 2001;104:
636 –41.
30. The GUSTO-V Investigators. Reperfusion therapy for acute myocar-
dial infarction with fibrinolytic therapy or combination reduced fi-
brinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the
GUSTO-V randomised trial. Lancet 2001;357:1905–14.
31. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in
combination with enoxaparin, abciximab, or unfractionated heparin:
the ASSENT-3 randomised trial in acute myocardial infarction.
Lancet 2001;358:605–13.
32. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial
comparing primary angioplasty with a strategy of short-acting
thrombolysis and immediate planned rescue angioplasty in acute
myocardial infarction: the PACT trial. PACT investigators.
Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll
Cardiol 1999;34:1954 –62.
33. Williams DO, Braunwald E, Thompson B, et al. Results of percuta-
neous transluminal coronary angioplasty in unstable angina and non–
Q-wave myocardial infarction. Observations from the TIMI IIIB
Trial. Circulation 1996;94:2749–55.
34. Ambrose JA, Almeida OD, Sharma SK, et al. Adjunctive thrombolytic
therapy during angioplasty for ischemic rest angina. Results of the
TAUSA Trial. TAUSA Investigators. Thrombolysis and Angioplasty
in Unstable Angina trial. Circulation 1994;90:69–77.
35. Mehran R, Ambrose JA, Bongu RM, et al. Angioplasty of complex
lesions in ischemic rest angina: results of the Thrombolysis and
Angioplasty in Unstable Angina (TAUSA) Trial. J Am Coll Cardiol
1995;26:961–6.
36. Wharton TP, Jr, McNamara NS, Fedele FA, Jacobs MI, Gladstone
AR, Funk EJ. Primary angioplasty for the treatment of acute myocar-
dial infarction: experience at two community hospitals without cardiac
surgery. J Am Coll Cardiol 1999;33:1257–65.
1718 Grines et al. JACC Vol. 39, No. 11, 2002
Transfer for Primary PTCA vs. On-Site Thrombolysis June 5, 2002:1713–9
37. Weaver WD, Parsons L, Every N. Primary coronary angioplasty in
hospitals with and without surgery backup. J Invas Cardiol 1995;7:
34–9F.
38. Ayres M. Coronary angioplasty for acute myocardial infarction in
hospitals without cardiac surgery. J Invas Cardiol 1995;7:40–6F.
39. Grines LL, Wharton TP, Balestrini C, et al. Should high-risk acute
myocardial infarction patients admitted to non-surgical hospitals be
transferred for primary PTCA or receive it on site? Circulation
2000;102 Suppl II:II-386.
40. Aversano T, Aversano LT, Passamani E, et al. Thrombolytic
therapy vs. primary percutaneous coronary intervention for myo-
cardial infarction in patients presenting to hospitals without on-site
cardiac surgery. A randomized controlled trial. JAMA 2002;287:
1943–51.
41. Smith SC, Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for
percutaneous coronary intervention (revision of the 1993 PTCA
guidelines): executive summary. J Am Coll Cardiol 2001;37:2215–
38.
APPENDIX
Clinical Sites (Number of Patients Enrolled)
Instituto Modelo de Cardiologia, Cordoba, Argentina (n 
39); St. Joseph Medical Center, South Bend, Indiana (n 
29); St. Charles Medical Center, Bend, Oregon (n  23);
Wausau Hospital, Wausau, Wisconsin (n  14); Oulu Uni-
versity Hospital, Oulu, Finland (n 13); New York University
Medical Center/Brooklyn Hospital, New York, New York
(n  7); William Beaumont Hospital, Royal Oak, Michigan
(n  4); Sanatorio Los Arroyos, Rosario, Argentina (n  3);
Allegheny General Hospital, Pittsburgh, Pennsylvania (n 2);
Riverside Methodist Hospital, Columbus, Ohio (n  1);
Oakwood Hospital, Dearborn, Michigan (n  1); and Jewish
Hospital, Louisville, Kentucky (n  1).
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